An artificial intelligence-powered precision cardiovascular medicine company named Cardio Diagnostics CDIO has launched a first-of-its-kind platform called Actionable Clinical Intelligence or ACI, that offers new epigenetic and genetic insights to clinicians prescribing the company’s Epi+Gen CHD and PrecisionCHD tests. Epi+Gen CHD is a powerful test that predicts the three-year risk for a coronary heart disease (CHD) event – a heart attack – and PrecisionCHD is a test for the detection of CHD.

一家名为Cardio Diagnostics CDIO的人工智能精密心血管医学公司推出了其首创的称为Actionable Clinical intelligence或ACI的平台，该平台为临床医生提供了新的表观遗传学和遗传学见解，为该公司的Epi+Gen CHD和PrecisionCHD测试开处方。Epi+Gen CHD是一种强大的测试，可预测冠心病（CHD）事件（心脏病发作）的三年风险，而PrecisionCHD是检测CHD的测试。

These AI-powered integrated genetic-epigenetic clinical tests only require a simple blood draw that can be performed at home or in provider settings without the need to wait weeks or months to get tested. Results from both of these laboratory-developed tests (LDTs) are coupled to the ACI platform. By merging LDT results with a patient’s unique epigenetic and genetic biomarkers and clinical information, ACI can provide deeper and actionable insights to clinicians about factors driving the patient’s CHD. Insights include the relative contribution of each of the patient’s biomarkers to CHD, evidence on the role of these biomarkers in CHD pathogenesis and changes in the measured biomarkers over time in response to lifestyle and therapeutic interventions.

这些人工智能支持的综合遗传表观遗传学临床测试只需要简单的抽血，就可以在家里或提供者的环境中进行，而无需等待数周或数月才能进行测试。这两个实验室开发的测试（LDT）的结果都与ACI平台耦合。通过将LDT结果与患者独特的表观遗传和遗传生物标志物以及临床信息相结合，ACI可以为临床医生提供有关驱动患者冠心病因素的更深入和可行的见解。见解包括每个患者生物标志物对冠心病的相对贡献，这些生物标志物在冠心病发病机制中的作用的证据，以及随着时间的推移，随着生活方式和治疗干预措施的变化，测量的生物标志物的变化。

With the goal of improving patient outcomes, this evidence-based information is tailored to each patient to help elucidate areas of concern and aid a clinician’s independent assessments. “With ACI, we are expanding the tools available to healthcare providers, enabling them to make personalized, data-driven decisions that are informed by a patient's unique genetic and epigenetic profile,” said Tim Dogan, Ph.D., Chief Technology Officer of Cardio Diagnostics.

为了改善患者的预后，针对每位患者量身定制了这种基于证据的信息，以帮助阐明关注的领域并帮助临床医生进行独立评估。心脏诊断首席技术官蒂姆·多根博士说：“通过ACI，我们正在扩大医疗保健提供者可用的工具，使他们能够根据患者独特的遗传和表观遗传特征做出个性化的数据驱动决策。”。

“Empowering clinicians with insights, such as those offered by ACI, furthers o.

“赋予临床医生以洞察力，例如ACI提供的见解，可以进一步促进o。